PF-06647020 (PF-7020), an antibody-drug conjugate (ADC) targeting protein tyrosine kinase 7 (PTK7), in patients (pts) with advanced solid tumors: Results of a phase I dose escalation and expansion study.

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Journal of Clinical Oncology

• Publication date

  2018-06-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1200/JCO.2018.36.15_SUPPL.5565
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• No references are available for this paper.

• Eukaryotic initiation factors: central factor associating mRNA translational plasticity during neuropathic pain progression

  2025cites this paper
• Conjunctival melanoma: comprehensive insights into clinical features, genetic alterations, and modern treatment approaches

  2025cites this paper
• The evolution of BRAF-targeted therapies in melanoma: overcoming hurdles and unleashing novel strategies

  2024cites this paper
• Research progress of antibody–drug conjugates in gynecologic cancer

  2024cites this paper
• Recent insights into the therapeutic strategies targeting the pseudokinase PTK7 in cancer

  2024cites this paper
• Revisiting targeted therapy and immunotherapy for advanced cholangiocarcinoma

  2023cites this paper
• Multidrug resistance in the standardized treatment of colon cancer harboring a rare fibrosarcoma B-type (BRAF) p.N581I mutation: a case report

  2023cites this paper
• 抗体偶联药物在晚期非小细胞肺癌中的研究进展

  2022cites this paper
• Precision drugging of the MAPK pathway in head and neck cancer

  2022cites this paper
• A review of recent advances on single use of antibody-drug conjugates or combination with tumor immunology therapy for gynecologic cancer

  2022cites this paper
• Illuminating kinase inhibitors biology by cell signaling profiling

  2022cites this paper
• Actively Targeted Nanomedicines in Breast Cancer: From Pre-Clinal Investigation to Clinic

  2022cites this paper
• First-in-Human Study of PF-06647020 (Cofetuzumab Pelidotin), an Antibody–Drug Conjugate Targeting Protein Tyrosine Kinase 7, in Advanced Solid Tumors

  2021cites this paper
• Ovarian cancer: new strategies and emerging targets for the treatment of patients with advanced disease

  2021cites this paper
• Emerging drugs for the treatment of adrenocortical carcinoma

  2021cites this paper
• Investigational antibody-drug conjugates in clinical trials for the treatment of breast cancer

  2021cites this paper
• Targeted therapy in advanced non-small cell lung cancer: current advances and future trends

  2021cites this paper
• Breast Cancer Treatment and Antibody Drug Conjugates: Beyond T-DM1

  2021cites this paper
• Prevalence of intratumoral regulatory T cells expressing neuropilin-1 is associated with poorer outcomes in patients with cancer

  2021cites this paper
• Tumor-Associated Macrophages: Critical Players in Drug Resistance of Breast Cancer

  2021cites this paper
• PtdIns(3,4,5)P3-dependent Rac exchanger 1 (P-Rex1) promotes mammary tumor initiation and metastasis

  2020cites this paper
• The physiological role of Wnt pathway in normal development and cancer

  2020cites this paper
• Antibody–Drug Conjugates for Cancer Therapy

  2020cites this paper
• Antibody–Drug Conjugates in Thoracic Malignancies: Clinical Trials Reveal Both Promise and Challenges

  2020cites this paper
• Antibody-drug conjugates in breast cancer: the chemotherapy of the future?

  2020cites this paper
• Antibody-drug conjugates for the treatment of ovarian cancer

  2020cites this paper
• Emerging therapeutic agents for advanced non-small cell lung cancer

  2020cites this paper
• Biologic therapy for advanced breast cancer: recent advances and future directions

  2020cites this paper
• Identification of drivers of breast cancer invasion by secretome analysis: insight into CTGF signaling

  2020cites this paper
• A view on drug resistance in cancer

  2019cites this paper
• Antibody-Drug Conjugates in Breast Cancer: a Comprehensive Review

  2019cites this paper
• Antibody-drug conjugates for lung cancer in the era of personalized oncology.

  2019cites this paper
• First insights for targeted therapies in odontogenic myxoma

  2019cites this paper
• Precision medicine for human cancers with Notch signaling dysregulation (Review)

  2019cites this paper
• Antibody drug conjugates in thoracic malignancies.

  2018cites this paper